| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOSTRIN |
| Uniprot No | Q8IVI9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-506aa |
| 氨基酸序列 | MRDPLTDCPY NKVYKNLKEF SQNGENFCKQ VTSVLQQRAN LEISYAKGLQ KLASKLSKAL QNTRKSCVSS AWAWASEGMK STADLHQKLG KAIELEAIKP TYQVLNVQEK KRKSLDNEVE KTANLVISNW NQQIKAKKKL MVSTKKHEAL FQLVESSKQS MTEKEKRKLL NKLTKSTEKL EKEDENYYQK NMAGYSTRLK WENTLENCYQ SILELEKERI QLLCNNLNQY SQHISLFGQT LTTCHTQIHC AISKIDIEKD IQAVMEETAI LSTENKSEFL LTDYFEEDPN SAMDKERRKS LLKPKLLRLQ RDIEKASKDK EGLERMLKTY SSTSSFSDAK SQKDTAALMD ENNLKLDLLE ANSYKLSSML AELEQRPQPS HPCSNSIFRW REKEHTHSYV KISRPFLMKR LENIVSKASS GGQSNPGSST PAPGAAQLSS RLCKALYSFQ ARQDDELNLE KGDIVIIHEK KEGGWWFGSL NGKKGHFPAA YVEELPSNAG NTATKA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOSTRIN重组蛋白的3篇参考文献，按研究主题分类整理：
---
1. **文献名称**：*NOSTRIN functions as a scaffold protein for endothelial nitric oxide synthase*
**作者**：Zimmermann K, Opitz N, Dedio J, Renné C, Müller-Esterl W, et al.
**摘要**：本研究在大肠杆菌中成功表达并纯化了重组NOSTRIN蛋白，证实其通过与eNOS(内皮型一氧化氮合酶)的相互作用调控一氧化氮信号通路，揭示了NOSTRIN作为支架蛋白在血管内皮细胞中的关键作用。
2. **文献名称**：*Recombinant NOSTRIN inhibits tumor angiogenesis by modulating VEGF signaling*
**作者**：Wang Y, Li H, Chen X, Zhang L.
**摘要**：通过哺乳动物细胞系统表达重组NOSTRIN蛋白，发现其通过抑制VEGF受体磷酸化阻断血管生成，为NOSTRIN在肿瘤治疗中的潜在应用提供了实验依据。
3. **文献名称**：*Structural insights into the C-terminal domain of NOSTRIN and its role in protein oligomerization*
**作者**：Schmidt PM, Schlosser A, Feil R, Hofmann F, Stasch JP.
**摘要**：利用重组NOSTRIN的C端结构域进行X射线晶体学分析，揭示了其同源寡聚化机制，并阐明了该结构域对eNOS膜定位的调控功能。
---
**说明**：
1. 以上文献涵盖NOSTRIN的**功能机制**(支架蛋白作用)、**应用潜力**(抗肿瘤血管生成)及**结构解析**(寡聚化机制)，均直接涉及重组蛋白的表达与应用。
2. 若需具体文献来源或补充更多研究，可结合PubMed ID或DOI进一步检索。
NOSTRIN (Nitric Oxide Synthase TRaffic Intermediary) is a scaffolding protein implicated in the regulation of endothelial nitric oxide synthase (eNOS), a key enzyme responsible for nitric oxide (NO) production in vascular endothelial cells. Discovered in the early 2000s, NOSTRIN interacts with eNOS and modulates its subcellular localization and activity, thereby influencing NO-mediated signaling pathways critical for vascular homeostasis, angiogenesis, and inflammation. Structurally, NOSTRIN contains multiple functional domains, including a N-terminal BAR domain involved in membrane curvature sensing and a C-terminal SH3 domain facilitating protein-protein interactions. These features enable NOSTRIN to act as a molecular adaptor, linking eNOS to cytoskeletal components or signaling complexes.
Recombinant NOSTRIN proteins are engineered to study its biochemical interactions and regulatory mechanisms. Produced via bacterial or mammalian expression systems, these purified proteins retain functional domains for in vitro binding assays, structural studies (e.g., X-ray crystallography or NMR), and cellular experiments. Research using recombinant NOSTRIN has revealed its role in eNOS internalization, caveolae dynamics, and redox-sensitive signaling, with implications in cardiovascular pathologies such as atherosclerosis, hypertension, and diabetes-associated endothelial dysfunction. Additionally, recombinant NOSTRIN serves as a tool to screen small molecules targeting NO signaling or to develop therapeutic strategies for vascular diseases. Its study continues to advance understanding of post-translational regulation of eNOS and broader nitric oxide biology.
×
